Research Article

Establishment and Validation of a Nomogram Prognostic Model for Epithelioid Hemangioendothelioma

Table 2

Survival rate and univariate analysis of all EHE patients.

CharacteristicOSCSS
Median (m)1 y (%)5 y (%)10 y (%)1 y (%)5 y (%)10 y (%)

All patients10076.557.448.277.359.052.4
Sex0.44580.2717
 Male9774.955.645.174.855.648.3
 Female12077.758.649.678.861.255.1
Race0.54870.6404
 White10077.759.048.579.060.252.4
 Black10073.851.848.171.953.953.9
 Other (Asian)11252.450.143.962.052.252.2
Staging<0.0001<0.0001
 LocalizedUndefined88.580.573.189.681.780.4
 Regional18283.266.057.086.570.364.7
 Distant2963.337.527.463.038.629.6
 Unknown7977.753.142.4
Degree of differentiation<0.0001<0.0001
 Good23888.477.972.691.680.274.3
 Poor1957.437.133.760.540.637.0
 Unknown8476.155.244.3
Primary location<0.0001<0.0001
 Head and neckUndefined84.275.665.391.084.881.1
 Lung4666.547.037.367.943.937.8
 Liver19975.358.753.878.461.151.7
 Bone (soft tissue)18583.764.753.984.167.766.3
 Other6773.351.338.5
Surgery<0.0001<0.0001
 No3463.940.530.466.142.734.0
 Yes23788.274.065.288.074.870.0
 Unknown1762.234.629.6
Chemotherapy<0.0001<0.0001
 No18582.266.557.083.869.462.4
 Yes2060.931.820.960.530.822.9
Radiotherapy0.00020.002
 No13579.362.952.180.063.955.8
 Yes2967.239.435.567.941.940.3

EHE: epithelioid hemangioendothelioma; OS: overall survival; CSS: cancer-specific survival; 1 y: 1 year; 5 y: 5 years; 10 y: 10 years.